Key clinical point: A dose of 300 mg secukinumab vs placebo showed rapid and significant improvements in the signs and symptoms of psoriatic arthritis (PsA) along with a tolerable safety profile in a US-only cohort of biologic-naive patients with PsA.
Major finding: At week 16, a significantly higher proportion of patients receiving 300 mg secukinumab vs placebo achieved ≥20% (odds ratio [OR] 3.51; P = .0011) , ≥50% (OR 6.30; P = .0038), and ≥70% (OR 10.50; P = .0243) improvement in American College of Rheumatology score, with response maintained through week 52. Diarrhea (5.8%), hypertension (4.9%), and upper respiratory tract infections (5.8%) were the most common adverse events, mostly of mild or moderate severity.
Study details: This phase 4 CHOICE study included 258 biologic-naive patients with moderate-to-severe PsA who were randomly assigned to receive 300 mg secukinumab, 150 mg secukinumab, or placebo.
Disclosures: This study was supported by Novartis Pharmaceuticals Corporation. Four authors declared being employees and shareholders of Novartis Pharmaceuticals Corporation and other authors reported ties with various sources, including Novartis.
Source: Nguyen T et al. Secukinumab in US biologic-naive patients with psoriatic arthritis: Results from the randomized, placebo-controlled CHOICE study. J Rheumatol. 2022 (Apr 15). Doi: 10.3899/jrheum.210912